Myocardial Infarction Genetics Consortium (MIGen)

This project started in 1997 when we worked with Dr. Chris O’Donnell to recruit patients hospitalized at MGH with early MI (men<50 and women<60 with MI).  With that collection as a foundation, we have expanded to include collaborators from around the world who have a similar interest in the genetics of early-onset heart attack.  Key … Read more

Global Lipids Genetics Consortium (GLGC)

This project started in 2006 with a genome-wide association analysis for plasma lipids within the Diabetes Genetics Initiative Study led by D. Altshuler and L. Groop.  With that study as a foundation, we have expanded to include investigators from around the world who have a similar interest in the genetics of plasma lipids.  The current … Read more

Amit Khera

M.D. Post-Doctoral Research Fellow Amit seeks to combine human genetics, traditional epidemiology, and bioinformatics approaches to gain insights into cardiometabolic traits and their relationship to atherosclerotic phenotypes.  Past research experience has included work with Dr. Daniel Rader implementing translational approaches to understanding lipid metabolism and Drs. Samia Mora / Paul Ridker to study biomarkers of risk prediction at the population level.  He completed his … Read more

Qiuyu Martin Zhu

M.D., Ph.D. Post-Doctoral Research Fellow Qiuyu Martin Zhu is a Research Fellow investigating novel non-lipid pathways leading to myocardial infarction. He combines human genetics and experimental approaches to decipher the impact of human genetic variations on coronary artery diseases. Martin completed clinical training in Internal Medicine and Cardiology in China. He studied the regulation of … Read more

Krishna Aragam

M.D., M.S. Post-Doctoral Research Fellow Krishna aims to harness human genetic variation for the study of coronary artery disease and related cardiovascular risk factors. His particular interest lies in the clinical translation of human genetic data to improve risk stratification for primary and secondary cardiovascular prevention.  He has been involved with basic science investigations in atherosclerosis … Read more

George Hindy

M.D., Ph.D. Post-Doctoral Research Fellow George’s research focuses on investigating causal molecular pathways involved in cardio-metabolic diseases through analysis of large-scale genomic and other molecular data in human populations. During his doctoral and postdoctoral work at Lund University, he studied interactions between genetic and environmental factors involved in type 2 diabetes and coronary heart disease … Read more

Connor Emdin

Ph.D. Post-Doctoral Research Fellow Connor has a particular interest in the use of human genetics to identify novel causal risk factors for cardiometabolic disease and to identify beneficial and adverse effects of therapeutics. He completed his undergraduate degree in biochemistry at the University of Toronto before completing a DPhil in cardiovascular epidemiology (2013-2016) at the … Read more

Mary Haas

Ph.D. Post-Doctoral Research Fellow Mary is a research fellow investigating the prioritization and functional translation of human genetic variation into novel genes affecting the development of cardiovascular disease and hyperlipidemia. Originally from Alaska, she completed undergraduate education in biology and chemistry at Williams College. She received her Ph.D. from Harvard University researching the role of … Read more

Shamsudheen Karuthedath Velarikkal

Ph.D Post-Doctoral Research Fellow Shamsudheen Karuthedath Velarikkal completed MSc in Biotechnology and worked as a research fellow for two years at CSIR Institute of Genomics and Integrative Biology, India, where he worked on various aspects of pathogenomics. He finished his PhD from the same institute by studying genomics of rare genetic disorders in Indian population. … Read more

Taiji Mizoguchi

M.D., Ph.D. Post-Doctoral Research Fellow Taiji Mizoguchi is a Research fellow investigating the efficacy of gene therapy for atherogenic dyslipidemia. He particularly focuses on in vivo genome editing technologies as tools to modify therapeutic target genes, which are associated with CVD. He graduated from Kobe University School of Medicine in 2008, thereafter finished his clinical practice in … Read more